biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > I sure like this Jon

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Oct 04, 2023 2:37pm

174 Views

Post# 35669545

RE:RE:RE:RE:RE:RE:I sure like this Jon

not sure it's the same thing. i mean, to waste 15+ years of your life on a biotech scam and still can't let it go is more of a disturbing obsession. maybe you can't fathom the idea that you got this one so wrong. why did it fail? simple....there is no utility to XB3. for some reason, you just can't accept that

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload